65,437 trials
Juvenile Psoriatic Arthritis · Enthesitis-related Arthritis
Primary: Number of Participants Experiencing a Flare During Treatment Period 2 — 10; 21 Participants — p=<0.001
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells · Blasts More Than 20 Percent of Peripheral Blood White Cells · Myelodysplastic/Myeloproliferative Neoplasm
Primary: Maximum Tolerated Dose of Ruxolitinib Phosphate (Phase I) — NA Dose in Milligrams
Head and Neck Neoplasms · Malignant Neoplasm of Vertebral Column
Primary: Number of Participants Undergoing Image-guided Cryoablation of a Head, Neck, or Spine Tumor With Adverse Events — 3; 0 participants
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
Stroke · Vitamin D
Primary: Number of Participants With Poor Stroke Outcome at Hospital Discharge as Measured by the Modified Rankin Scale (mR 3-6) — 84; 99; 96; 87 Participants
Crohn's Disease
Primary: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 — 21.1; 38.9 percentage of participants — p=<0.0001
Mydriasis · Dilation
Primary: Pupil Diameter (Change From Max) — -1.69; -0.69 mm — p=<0.0001
Duchenne Muscular Dystrophy
Primary: Forced Vital Capacity — 1.4; 1.4; 1.5 liters — p=0.3904
Parkinson's Disease
Primary: Feasibiilty of Ketogenic Diet - Retention (Co-primary Endpoint) — 15 Participants
Chronic Migraine
Primary: Change in VAS Pain Severity — 3.23; 5.36 units on a scale — p=0.1
Physical Activity
Primary: Weekly Walking Minutes — 189.5; 206.7 minutes/week
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.32; -5.19; -5.39 VMS per day — p=<0.001
Pharmacokinetics · Safety · Food-drug Interaction
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 7; 4; 6; 6 Participants
Stress · Psychological Stress · Child Maltreatment
Primary: Change in Stressor Demands, as Measured by Ecological Momentary Assessment (EMA) — -.0950; .0009 score on a scale
Kidney Cancer · Renal Cell Carcinoma
Primary: Total Operative Time — 163; 173.5 minutes